Chelsea Albanese, DO
Internal Medicine · Delray Beach, FLNPI 1003288838
Payments from drug & device makers
Across 159 payments — averaging $20.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exact Sciences$449
- Novo Nordisk$374
- Pfizer$318
- AbbVie$279
- Amgen$212
- Lilly USA, LLC$177
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,219100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exact Sciences | 18 | $449 |
| Novo Nordisk | 21 | $374 |
| Pfizer | 16 | $318 |
| AbbVie(2 entities) | 13 | $279 |
| Amgen | 12 | $212 |
| Lilly USA, LLC | 7 | $177 |
| GSK | 10 | $166 |
| Amarin Pharma, Inc. | 9 | $162 |
| Idorsia Pharmaceuticals US Inc | 6 | $108 |
| Astellas Pharma US Inc | 4 | $100 |
| Daiichi Sankyo Inc. | 4 | $90 |
| Novartis | 5 | $85 |
| Smith+Nephew | 2 | $82 |
| Boston Scientific | 3 | $72 |
| Almatica Pharma LLC | 3 | $57 |
| Lucid Diagnostics Inc. | 3 | $50 |
| Kowa Pharmaceuticals America, Inc. | 2 | $39 |
| Merck | 3 | $38 |
| Biosense Webster, Inc. | 1 | $34 |
| Johnson & Johnson | 2 | $32 |
| Shield Therapeutics Inc | 1 | $29 |
| Edwards Lifesciences | 1 | $28 |
| IBSA Pharma Inc. | 1 | $25 |
| Abiomed | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Tactile Systems Technology Inc | 1 | $21 |
| Abbott | 1 | $18 |
| Medtronic | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Alkermes, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Linus Health, Inc. | 1 | $14 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $12 |
How this compares
$3,219 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 98 | $125,791 |
| EliquisApixaban | 80 | $101,488 |
| MounjaroTirzepatide | 31 | $33,586 |
| XareltoRivaroxaban | 15 | $23,234 |
| ProliaDenosumab | 12 | $20,607 |
| JanuviaSitagliptin Phosphate | 12 | $19,370 |
| MyrbetriqMirabegron | 15 | $13,847 |
| SynthroidLevothyroxine Sodium | 118 | $10,351 |
| Eszopiclone | 40 | $7,806 |
| Levothyroxine Sodium | 613 | $6,325 |
| Rosuvastatin Calcium | 565 | $6,203 |
| Atorvastatin Calcium | 652 | $5,934 |
| Omeprazole | 352 | $4,227 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 13 | $4,063 |
| Escitalopram Oxalate | 298 | $4,040 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $374 | $125,79198 claims |
| PfizerEliquis | $318 | $101,48880 claims |
| Lilly USA, LLCMounjaro | $177 | $33,58631 claims |
| Johnson & JohnsonXarelto | $32 | $23,23415 claims |
| AmgenProlia | $212 | $20,60712 claims |
| MerckJanuvia | $38 | $19,37012 claims |
| Astellas Pharma US IncMyrbetriq | $100 | $13,84715 claims |
| AbbVieSynthroid | $279 | $10,351118 claims |
| GSKArexvy, Shingrix | $166 | $7,66329 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Delray Beach
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.